Parallel VENTANA IHC and RT-PCR of ALK status in non-small cell lung cancer and response to crizotinib.

C. Xu,Wen-Xian Wang,Meiyu Fang,Yanping Chen,Yu Chen,Zhong Ly,Fang-fang Chen,Wu Zhuang,Gen Lin,Xiaohui Chen,Haipeng Xu,Yun-jian Huang,Yan-Fang Guan,Xin Yi,Tangfeng Lv,Xiao-jiang Wang,Yi Shi,Xiandong Lin,Gang Chen,Yong Song

Parallel VENTANA IHC and RT-PCR of ALK status in non-small cell lung cancer and response to crizotinib.

2017

11623Background: Advanced NSCLC patients who harbor (ALK) rearrangement were sensitive to crizotinib. However, not all ALK-positive patients benefit equally from crizotinib. A method for determinin...

Keywords:

Pathology
Lung cancer
Crizotinib
Medicine
Immunohistochemistry
Real-time polymerase chain reaction
Oncology
non small cell
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations